Pancreatic Ductal Adenocarcinoma (PDAC) Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access

Table of Contents

• An aggressive, lethal cancer beginning in the ducts of the pancreas
• Figure 1.1. Signs and symptoms of PDAC
• Table 1.1. Risk factors associated with PDAC
• PDAC is a lethal cancer with limited treatments but many potentially actionable targets
• Table 1.2. Staging of disease in PDAC
• Table 1.3. Five-year survival rates for pancreatic cancer

• Disease definition
• Table 2.1. Incident populations of PDAC in the US, EU4 and UK
• Drug-treated PDAC patients
• Table 2.2. Drug-eligible and drug-treated PDAC patients by stage

• Diagnosis overview
• Figure 3.1. Oncologist-reported PDAC patient segmentation
• Diagnostic journey of PDAC patients - timely diagnosis is challenging due to the nature of the symptoms
• Treatment flows for resectable and borderline resectable patients
• Table 3.1. Surgery-eligible PDAC patient segments
• Treatment of resectable and borderline resectable PDAC
• Figure 3.2. Neoadjuvant therapy use prior to surgery in surgery-eligible PDAC patients
• Figure 3.3. Adjuvant therapy in patients who have undergone resection
• Physician insights on drug treatment in surgery-eligible patients
• Treatment of locally advanced and metastatic patients
• Table 3.2. Unresectable PDAC patient segments
• Treatment of metastatic patients
• Figure 3.4. Percentage of oncologists who prescribe Olaparib to BRCA+ patients as a maintenance tx
• FOLFIRNIOX and gemcitabine-based therapies are the backbone of PDAC treatment
• Figure 3.5. Oncologist-reported current treatment share for locally advanced and metastatic patients: 1st-line setting
• Figure 3.6. Oncologist-reported current treatment share for locally advanced and metastatic patients: 2nd-line setting
• Identification of druggable targets guides treatment decisions in unresectable patients
• Table 3.3. Genetic and somatic testing of PDAC patients
• Figure 3.7. Oncologist-reported percentage of PDAC patients tested for germline and somatic mutations
• Key treatment dynamics that shape disease management and drug use in PDAC
• Table 3.4. Must-know PDAC treatment dynamics for now and the future
• PDAC market evolution
• Figure 3.8. Important dynamics of PDAC market evolution

• Overview
• Figure 4.1. Top unmet needs in PDAC
• Figure 4.2. Medical Oncologist unmet needs in PDAC
• Unmet needs - Physician perspectives
• Clinical outcomes that impact prescribing habits - Physician perspectives
• Figure 4.3. Importance of clinical outcomes on prescribing habits in 1st and 2nd line mPDAC

• Overview
• Figure 5.1. Percentage of oncologists rating target as “promising” for PDAC
• Physician commentary on emerging therapy targets
• Late-stage clinical development for metastatic PDAC
• Table 5.1. Comparison of selected late-stage trials in metastatic PDAC
• Early-stage clinical development for metastatic PDAC
• Table 5.2. Selected ongoing Phase 2 clinical trials
• Early-stage clinical development for metastatic PDAC (continued)
• Table 5.2. Selected ongoing Phase 2 clinical trials (continued)
• Novel therapy trial failure in PDAC and a new approach to trial design
• Table 5.3. Focus on the Phase 3 CanStem111P study of napabucasin

• Overview
• Table 6.1. Current therapy pricing, US 2022
• Figure 6.1. Reimbursement and Access considerations for emerging therapies in PDAC

• Primary market research approach
• Epidemiology methodology
• Appendix: List of abbreviations used in PDAC report
• Appendix: List of abbreviations used in PDAC report (continued)

Samples

Companies Mentioned

• Novartis
• Pancreatic Cancer Action Network
• Panbela Therapeutics
• BioLineRx
• Astellas Pharma
• TME Pharma
• Merck Sharp & Dohme
• SynerGene Therapeutics
• Ability Pharma
• AstraZeneca
• ERYTECH
• Cornerstone Pharmaceuticals
• Eli Lilly
• Pharmacyclics
• Halozyme Therapeutics
• Sumitomo Pharma
• FibroGen